Innovating Women’s Reproductive Health and Pregnancy Therapeutics ObsEva is a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to birth. Between the ages of 20 and 50, millions of women worldwide suffer from reproductive health conditions that affect their quality of life and their ability to conceive or may lead to complications during pregnancy. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and efficacy profiles. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with multiple development programs focused on treating endometriosis, uterine fibroids, and preterm labor. ObsEva is supported by top-tier investors and a globally recognized board and is well-positioned to establish a leadership position in women’s reproductive therapeutics.
Company Growth (employees)
Type
Private
HQ
Plan-les-Ouates, CH
Founded
2012
Size (employees)
29 (est)+12%
Website
obseva.com
ObsEva was founded in 2012 and is headquartered in Plan-les-Ouates, CH

Key People at ObsEva

Ernest Loumaye

Ernest Loumaye

Co-Founder & CEO

ObsEva Office Locations

ObsEva has an office in Plan-les-Ouates
Plan-les-Ouates, CH (HQ)
1228 Plan-les-Ouates

ObsEva Metrics

Summary Metrics

Founding Date

2012

Total Funding

$92.9 m

Latest funding size

$60 m

Time since last funding

over 1 year

Investors

ObsEva's latest funding round in November 2015 was reported to be $60 m. In total, ObsEva has raised $92.9 m

ObsEva Company Life

You may also be interested in